https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7330574/
Limitations of this study are that HC was used with patients already infected with Sars2 and it was not a double blind study. In addition, patients were given tx within 48 hours of admission compared to other studies where pts were given tx at any time during their hospitalization.
The pts not receiving HC and AZ had a death rate of 26% compared to 13.5% of the HC tx alone group. This study supports the use of HC as a tx for patients with severe symptoms who are hospitalized.
The Henry Ford Health system is also engaged in a pre-exposure preventive HC tx study which is ongoing and has not yet been completed. I think that they are recruiting among healthcare professionals who are likely to become exposed to Sars2. The name of the new study is the WHIP study.